Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy Adults

Sponsor

Reata Pharmaceuticals, Inc. (Industry)

Overall Status

Completed

CT.gov ID

NCT03264079

Collaborator

(none)

Enrollment

Location

Arm

Actual Duration (Days)

17.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This trial will study the impact of a strong CYP3A4 inhibitor (itraconazole) on the pharmacokinetics of bardoxolone methyl (RTA 402) in healthy adult subjects.

This is an open-label, fixed-sequence crossover pharmacokinetic (PK) study in healthy volunteers.

Subjects will complete a screening visit within 28 days of Study Day 1. Subjects must qualify for the study based on inclusion/exclusion criteria. For Period 1, all qualified subjects shall receive a single oral dose of bardoxolone methyl (10 mg) on Day 1. For Period 2, following a washout of 14 days, itraconazole (SPORANOX®) capsules (100 mg) will be administered as a 200-mg single daily dose on Study Days 15 through 27, with bardoxolone methyl (10 mg) administered on Day 18 (1 hour after itraconazole administration).

Bardoxolone methyl doses will be administered under fasted conditions. Itraconazole will be administered under fed conditions on Study Days 15-17, and Study Days 19-27.

On study Day 18, itraconazole will be administered under fasted conditions. Subjects will be confined beginning on Study Day -1 through the last blood sample collection on Study Day 9 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 28 during Period 2.

Condition or Disease	Intervention/Treatment	Phase
Healthy Volunteers	Drug: Bardoxolone methyl capsules 10 mg Drug: Itraconazole capsules 100 mg	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

16 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

All participants are placed into a one group to receive two interventions: one intervention during Period 1 and a second intervention during Period 2. For Period 1, all qualified subjects shall receive a single oral dose of bardoxolone methyl (10 mg) on Day 1. For Period 2, following a washout of 14 days, itraconazole (SPORANOX®) capsules (100 mg) will be administered as a 200-mg single daily dose on Study Days 15 through 27, with bardoxolone methyl (10 mg) administered on Day 18 (1 hour after itraconazole administration)All participants are placed into a one group to receive two interventions: one intervention during Period 1 and a second intervention during Period 2. For Period 1, all qualified subjects shall receive a single oral dose of bardoxolone methyl (10 mg) on Day 1. For Period 2, following a washout of 14 days, itraconazole (SPORANOX®) capsules (100 mg) will be administered as a 200-mg single daily dose on Study Days 15 through 27, with bardoxolone methyl (10 mg) administered on Day 18 (1 hour after itraconazole administration)

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Open-Label Study of the Effect of a Strong CYP3A4 Inhibitor (Itraconazole) on the Pharmacokinetics of Bardoxolone Methyl in Healthy Volunteers

Actual Study Start Date :

Oct 16, 2017

Actual Primary Completion Date :

Nov 13, 2017

Actual Study Completion Date :

Nov 13, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Bardoxolone methyl 10 mg and Itraconazole 200 mg Period 1: Bardoxolone methyl capsules 10 mg Period 2: two Itraconazole capsules 100 mg	Drug: Bardoxolone methyl capsules 10 mg One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial Other Names: RTA 402 Drug: Itraconazole capsules 100 mg Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial Other Names: Sporanox

Arm

Intervention/Treatment

Experimental: Bardoxolone methyl 10 mg and Itraconazole 200 mg

Period 1: Bardoxolone methyl capsules 10 mg Period 2: two Itraconazole capsules 100 mg

Drug: Bardoxolone methyl capsules 10 mg

One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial

Other Names:

RTA 402

Drug: Itraconazole capsules 100 mg

Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial

Other Names:

Sporanox

Outcome Measures

Primary Outcome Measures

Area under the plasma concentration-time curve of bardoxolone methyl from time 0 to the last measurable time point (AUC0-t). [28 days]
Area under the plasma concentration-time curve of bardoxolone methyl extrapolated to infinity (AUC0-inf) [28 days]
Maximum observed drug concentration (Cmax) in plasma of bardoxolone methyl [28 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Male or female and age is between 18 and 55 years, inclusive;
Female subjects of childbearing potential must not be planning a pregnancy, pregnant, or lactating, and must have a negative serum pregnancy test result before enrollment into the study, and must be willing to use contraception as specified or abstain from sexual activity for the duration of the study;
If male, subject must be surgically sterile or practicing an approved method of contraception, from initial study drug administration through 90 days after administration of the last dose of study drug;
If male, subject agrees to abstain from sperm donation through 90 days after administration of the last dose of study drug;
Body Mass Index (BMI) is ≥ 18 to ≤31 kg/m2, inclusive;
A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG), as judged by the investigator;
Must voluntarily sign and date each informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion Criteria:

History of clinically significant drug allergies, including allergies to any of the components of the investigational product and/or clinically significant food allergies as determined by the investigator;
Presence or history of any significant cardiovascular, gastrointestinal, hepatic, renal, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease, as determined by the investigator;
Presence of any other condition (including surgery) known to interfere with the absorption, distribution, metabolism, or excretion of medicines;
Known hypersensitivity to any component in the formulations of bardoxolone methyl, or SPORANOX®;
Requirement for any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements on a regular basis;
Use of any medications (over-the-counter and/or prescription medication), vitamins, and/or herbal supplements, within the 30-day period prior to study drug administration or within 5 half-lives (if known), whichever is longer;
Recent (6-month) history of drug or alcohol abuse;
B-type natriuretic peptide (BNP) level >200 pg/mL at screening;
Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or HIV antibodies (HIV Ab) at screening;
Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration;
Receipt of any investigational product within a time period equal to 10 half-lives of the product, if known, or a minimum of 30 days prior to study drug administration;
Positive screen results for drugs of abuse, alcohol, or cotinine at screening or Day -1;
Consumption of alcohol within 72 hours prior to study drug administration;
Consumption of grapefruit, grapefruit products, star fruit, star fruit products, or Seville oranges within the 72-hour period prior to study drug administration;
Use of tobacco or nicotine-containing products within the 6-month period preceding study drug administration;
Current enrollment in another clinical study;
Screening laboratory analyses that show any of the following abnormal laboratory results:

Alanine transaminase (ALT) or aspartate aminotransferase (AST) levels above the upper limit of normal (ULN);
Clinically significant abnormal ECG; ECG with QTc using Fridericia's correction formula (QTcF) > 450 msec is exclusionary;
Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive either bardoxolone methyl or itraconazole.